Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies may have an effect on the efficacy of lokivetmab. As with any immunological product, in rare cases, hypersensitivity reactions may occur. If such a reaction occurs, administer appropriate symptomatic treatment without delay.
No drug interactions were observed in field studies where lokivetmab was administered concomitantly with other veterinary medicines such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines.
Do not use in case of hypersensitivity to active substance or any of the excipients. Do not use in dogs weighing less than 3kg. The safety of Cytopoint has not been established during pregnancy and lactation. Therefore, it is not recommended during pregnancy or lactation, or in dogs intended for breeding.
Hypersensitivity, including anaphylaxis, could potentially occur in the case of accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.
Store at 2-8°C. Refrigerate. Do not freeze. Protect from light. Avoid excessive shaking.